Get the Daily Brief
Latest Biotech News
Prime Medicine reverses course – pursues FDA approval for prime‑editing therapy
Prime Medicine has reversed an earlier decision to shelve a gene‑editing program and will seek FDA approval for a prime‑editing therapy after treating only two patients, according to company...
Moderna pays big: upfront cash in global LNP patent settlement
Moderna agreed to settle long‑running patent litigation over lipid nanoparticle (LNP) delivery technology with Roivant’s Genevant and Arbutus, paying $950 million upfront and up to $2.25 billion...
FDA targets compounders: fresh warning letters hit GLP‑1 telehealth sellers
The U.S. Food and Drug Administration sent a new batch of warning letters—30 in the latest round—targeting telehealth companies that marketed compounded versions of GLP‑1 obesity drugs and made...
Theravance winds down R&D after phase III failure – major layoffs follow
Theravance Biopharma announced the end of its R&D organization and a 50% workforce reduction after its phase III trial of ampreloxetine failed to meet the primary endpoint. The company will pivot...
AGBT reveals high‑throughput sequencing arms race: Illumina faces new rivals
At the Advances in Genome Biology and Technology meeting, multiple companies unveiled high‑throughput sequencing updates that collectively threaten Illumina’s clinical pricing and capacity...
Cellanome R3200: live‑cell imaging tied to sequencing for longitudinal functional analysis
Cellanome commercialized the R3200 platform that integrates live‑cell imaging, AI segmentation, micro‑3D printing and sequencing to link phenotypes to transcriptomes in longitudinal experiments,...
GSK licenses Frontier’s siRNA assets: $40M upfront, near‑$1B upside
GlaxoSmithKline signed a global exclusive license with China’s Frontier Biotechnologies for two siRNA candidates in immunology, paying $40 million up front and up to $963 million in milestones....
UCB enters T‑cell engager race: $80M upfront for Antengene’s CD19xCD3 asset
UCB licensed ATG‑201, a CD19xCD3 T‑cell engager developed by Shanghai‑based Antengene, paying $80 million up front with up to $1.1 billion in milestones and tiered royalties. Antengene will...
Atrium Therapeutics spins out to focus on RNA therapies for cardiomyopathies
Atrium Therapeutics launched as a public company following Novartis’ acquisition of Avidity, carrying roughly $270 million in cash and two lead RNA‑delivery candidates targeting PRKAG2 syndrome...
Moderna to pay $950M upfront — settles long-running Covid vaccine patent fight
Moderna agreed to a near‑term settlement that will resolve long‑running patent litigation tied to its Covid‑19 vaccine. The company will pay $950 million upfront to Arbutus Biopharma and Roivant’s...
Theravance winds down R&D — halves workforce after Phase III failure
Theravance Biopharma announced an immediate strategic retrenchment after its lead candidate failed a pivotal Phase III study, prompting the company to terminate R&D activities and cut its...
UCB inks Antengene TCE pact: Belgian drugmaker steps into bispecific space
UCB struck licensing agreements with Shanghai‑based Antengene to enter the crowded T‑cell engager (TCE) arena, acquiring rights to Antengene’s CD19xCD3 candidate with a mix of upfront payments and...
GSK expands oligonucleotide and PAH bets: two deals push immunology and pulmonary pipeline
GSK closed a deal to license two Frontier Biotechnologies siRNA assets and separately bought 35Pharma to add a pulmonary hypertension candidate, executing a two‑pronged growth push into...
FDA tightens bar on gene therapies — Regenxbio, UniQure face fresh regulatory hurdles
The FDA pushed back on pivotal gene therapy submissions, citing trial design, control group and endpoint issues in public rejection letters and company disclosures. REGENXBIO received an FDA...
FDA clears Ascendis’ once‑weekly dwarfism shot: accelerated approval granted
The FDA granted accelerated approval to Ascendis Pharma’s once‑weekly TransCon CNP (Yuviwel) for children with achondroplasia, breaking BioMarin’s prior monopoly in the indication. The approval...
Blackstone backs Teva with $400M — funds Sanofi‑partnered anti‑TL1A development
Private equity firm Blackstone Life Sciences agreed to provide up to $400 million to support Teva’s development of duvakitug, an anti‑TL1A antibody partnered with Sanofi for inflammatory bowel...
Candid to go public via RallyBio reverse merger — $505M in new funding
Candid Therapeutics will go public through a reverse merger with RallyBio and simultaneously raised $505 million in a private placement to advance its T‑cell engager pipeline targeting autoimmune...
Sequencing arms race... Big vendors roll new high‑throughput options, price pressure hits Illumina
Industry announcements at AGBT and related venues signaled a sharpening competition for ultra‑high throughput sequencing: Element Biosciences, Ultima Genomics, Roche and Complete Genomics revealed...
Biotech funding roundup: $150M mental‑health play and top February rounds
Investors continued to fund health‑focused companies: Grow Therapy closed a $150 million Series D to expand employer and health‑system partnerships, while sector trackers flagged the largest...
Moderna settles long-running mRNA patent fight: $950M now, up to $2.25B possible
Moderna agreed to a major settlement with Arbutus Biopharma and Roivant’s Genevant, paying $950 million upfront to resolve patent claims tied to its Covid-19 vaccine, with contingent payments that...